The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index; 32 of the 64 sources its claims cite were checked for support.
The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol
Open accessAbstract
Background: There is currently renewed interest in the use of psychedelic therapy in the treatment of psychiatric disorders, including depression. The proposed systematic review will aim to identify, evaluate and summarise the psychological processes of change underlying psychedelic therapy for depression in the current literature and consider the implications these processes may have on the psychotherapy component of treatment. Methods: Scopus, PsycINFO, PubMed and Web of Science databases will be searched using relevant terms. Studies will be included if they discuss the use of a classic psychedelic to treat depression symptomology in an adult population and report or propose psychological processes responsible for depression symptom change. Two authors will independently screen articles, complete quality assessment tools and conduct data extraction. Empirical and non-empirical research will be extracted and synthesised separately. A narrative synthesis approach will be used to report psychological processes identified in the literature. Discussion: This systematic review will be the first to collate available evidence on the psychological processes associated with psychedelic therapy for depression. The preliminary nature of this research field is expected to result in the review having several limitations, namely heterogeneity between studies and the inclusion of limited empirical research. We intend for this review to present the current state of the literature, identify gaps and generate candidate variables that warrant further investigation. Systematic review: PROSPERO CRD42020197202. © 2022, The Author(s).
Overview
CoChat Summary
TL;DR
This is a systematic review protocol, not a completed review, aimed at identifying and synthesizing psychological processes underlying classic psychedelic therapy for depression. The authors plan a narrative synthesis of empirical and non-empirical literature on adults, using studies from 1990 onward.
Key findings
- Not stated in the paper.
- The review is expected to be the “first to collate available evidence” on psychological processes associated with psychedelic therapy for depression, but this is a projected contribution rather than a result.
- The protocol anticipates that heterogeneity between studies and “limited empirical research” will constrain synthesis.
- The authors note prior studies suggesting rapid antidepressant effects of psychedelics, including symptom reductions in treatment-resistant depression at 1 week and sustained reductions at 6 months, but these are background citations, not findings of this review.
Methods
- Protocol for a systematic review registered in PROSPERO (CRD42020197202) and planned to follow PRISMA-P and PRISMA guidance.
- Planned search of Scopus, PsycINFO, PubMed, and Web of Science for studies from 1990 to present; inclusion requires adult depression symptomology and reporting/proposing psychological processes tied to classic psychedelic treatment.
- Two reviewers will independently screen, extract data, and assess quality; empirical and non-empirical studies will be synthesized separately using a narrative synthesis approach.
Limitations
- The paper states that heterogeneity between studies and limited empirical research are expected limitations.
- It also states that the review will rely on narrative synthesis, which is “at increased risk” of researcher bias; the authors say they will try to minimize this through rigorous methods.
- Evident from the text: because this is only a protocol, it reports no study results and cannot yet assess the actual evidence base.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
24 Valid · 2 Not valid · 22 Not checked · 19 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These findings have been further supported by randomised trials, which found psilocybin-assisted psychotherapy to produce significant reductions in depression symptomology in individuals with major depressive disorder (MD D[17, 18];)”
§ The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol > Background
What the sources say
- Not checked — no full text of the sourcecites [17] Carhart-Harris RL, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402–11. source
- Supportedcites [18] Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiat. 2020;78(5):481–9. source
The Methods identify this as a randomized, waiting-list–controlled trial involving patients with major depressive disorder. The Results report significantly lower depression scores after psilocybin-assisted therapy than in the delayed-treatment group before treatment (P < .001 at both comparisons). This paper supports the claim as one of the cited trials. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“and those experiencing distress associated with life-threatening cancer [19, 20].”
§ The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol > Background
What the sources say
- Supportedcites [19] Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181–97. source
The Discussion reports that this randomized trial found large, significant decreases in depression measures among patients with life-threatening cancer who received psilocybin under supportive conditions. The Conclusions likewise describe substantial, enduring decreases in depressed mood. (LLM, conf=0.93)
- Supportedcites [20] Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–80. source
The Results (Primary outcomes; page not provided) report significant reductions in depression symptoms after psilocybin treatment. The Conclusions state that psilocybin was administered with psychotherapy to patients with cancer-related psychological distress and produced antidepressant effects. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“An open-label feasibility study reported significant symptom reductions in participants with treatment-resistant depression (TRD; defined as experiencing no improvements in depression symptoms despite two courses of antidepressant treatment) 1 week post-treatment [15].”
§ The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol > Background
What the sources say
- Supportedcites [15] Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619–27. source
The Study design and participants section identifies this as an open-label feasibility study of patients whose depression had not improved despite two adequate antidepressant courses. The results passage reports significantly reduced depression scores from baseline to 1 week after treatment. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The amygdala has been found to show greater responsiveness to emotional faces 1 day after psilocybin consumption and greater responsiveness to fearful versus neutral faces was related to improved depressive symptoms 1 week post-intervention [36].”
§ The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol > Background > Neurobiological processes in psychedelic treatment Exactly how classic psychedelics may work to reduce depression symptoms is still largely unknown, although several potential mechanisms have been proposed. Increased functional connectivity within the default mode network (DMN), a group of brain regions which show increased activity during rest and decreased activity during cognitively demanding tasks, as well as decreased functional connectivity between executive networks and the DMN, are associated with the pathophysiology of MDD [26, 27]. A number of studies have demonstrated that classic psychedelics acutely reduce activity and internal functional connectivity within the DMN [28, 29], potentially reducing abstracted (perceptually decoupled) and self-referential rumination, a hallmark of depressotypic thinking [30–32]. However, similar changes in DMN connectivity have been observed post-administration of sertraline [33], a widely used selective serotonin reuptake inhibitor, suggesting that these changes may not be psychedelic-specific [34]. There is some evidence to suggest that the psychedelic state produces co-activation between the DMN and task positive networks (a network of brain regions which activate during attention demanding tasks), two networks which are usually anti-correlated [35]. However, these findings have not been replicated in a more recent investigation into the impact of ayahuasca on the DMN [28] so it is unclear as to whether this co-activation may be contributing to the novel experiences and outcomes which occur during psychedelic-assisted psychotherapy [35]. Several other neurobiological mechanisms of action have been suggested to contribute to the antidepressant effects of psychedelics. The amygdala has been found to show greater responsiveness to emotional faces 1 day after psilocybin consumption and greater responsiveness to fearful versus neutral faces was related to improved depressive symptoms 1 week post-intervention [36]. This may indicate that psilocybin has a direct effect on apathy symptoms associated with depression. Additionally, decreased functional connectivity between the amygdala and ventromedial prefrontal cortex have been found during face processing tasks 1 day post-psilocybin consumption [37]. During the same task, the amygdala and ventromedial prefrontal cortex were found to have increased functional connectivity with the occipital lobe and parietal cortex [37]. Taken together, these preliminary findings have been speculated to suggest that psilocybin may encourages increased emotional sensitivity and acceptance 1 day post-treatment [37]. Animal studies have suggested that psychedelics increase neuroplasticity, possibly through increased cortical glutamate, brain-derived neurotrophic factor, and activation of the tropomyosin receptor kinase B [34, 38, 39]. Other animal studies have proposed that psychedelics may elicit their antidepressant effect through anti-inflammatory processes, by inhibiting proinflammatory cytokines TNF-α and IL-6, which have been found to be associated with depression [40]. However, more research is required to comprehensively understand how psychedelics may be acting on the brain to alleviate depressive symptoms.
What the sources say
- Supportedcites [36] Roseman L, Demetriou L, Wall MB, Nutt DJ, Carhart-Harris RL. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacol. 2018;142:263–9. source
The Discussion reports increased amygdala responses to emotional faces one day after psilocybin treatment for treatment-resistant depression. It also reports that increased responses to fearful versus neutral faces were related to a successful clinical outcome one week later. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Undergoing a mystical-type experience during the acute effects of a psychedelic has been associated with healthy volunteers reporting an improvement in their wellbeing [51, 52], and reductions in depression symptoms in participants with life-threatening cancer [19, 20].”
§ The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol > Background > Set and setting: psychological processes in psychedelic-assisted psychotherapy
What the sources say
- Supportedcites [51] Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacol. 2011;218(4):649–65. source
The Discussion reports that 94% of volunteers said their experience at one or both of the two highest psilocybin doses increased their well-being or life satisfaction moderately or very much. It also describes dose-related mystical-type experiences and persisting positive effects in this group of healthy volunteers. Page numbers are not provided in our copy. (LLM, conf=0.93)
- Supportedcites [52] Griffiths RR, Johnson MW, Richards WA, Richards BD, Jesse R, MacLean KA, et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol. 2018;32(1):49–69. source
The Introduction describes psilocybin-occasioned mystical-type experiences in healthy volunteers and says participants often attribute enduring positive changes in well-being to them. This supports the claim about volunteers reporting improved well-being; the cited part does not require evidence about cancer-related depression. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
27 more claims · 11 with their cited sources checked
Create a free account to see all 67 claims and every source verdict.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 9
Citations
Cites
PRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223
Rayyan-a web and mobile app for systematic reviews.
Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0384-4 · Cited by 26,092 · cited 2×
“Study selection Identified articles will be collated into Rayyan [67] and duplicates removed.”
MethodDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Methodological quality and synthesis of case series and case reports
Murad, M. H., Sultan, S., Haffar, S., & Bazerbachi, F. (2018) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2017-110853 · Cited by 2,242 · cited 1×
“A modified version of Murad and colleague’s methodological quality assessment tool will be used to assess quantitative studies [68].”
MethodGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 2×
“Several trials have reported psilocybin to produce signi cant and long-lasting improvements for those with treatment resistant depression (15, 16) and depression associated with life threatening cancer (17, 18).”
BackgroundNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698 · cited 1×
“Undergoing a mystical experience has been associated with positive wellbeing in healthy volunteers (43, 44), and reductions in depression symptoms in participants with life-threatening cancer (18, 45).”
BackgroundCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 1×
“Several trials have reported psilocybin to produce signi cant and long-lasting improvements for those with treatment resistant depression (15, 16) and depression associated with life threatening cancer (17, 18).”
BackgroundThe default mode network and self-referential processes in depression
Sheline, Y. I., Barch, D. M., Price, J. L., Rundle, M. M., Vaishnavi, S. N., Snyder, A. Z., Mintun, M. A., Wang, S., Coalson, R. S., & Raichle, M. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812686106 · Cited by 1,480
Research works printed but not linked: 3
- Torres CM. Archaeological evidence for the antiquity of psychoactive plant use in the Central Andes. Annuli dei Musei Civici Roverero. 1996;11:291–326.
- Grof S, editor Psycholytic and psychedelic therapy with LSD: Toward an integration of approaches. Address to the Conference of the European Association for Psycholytic Therapy, Frankfurt, West Germany; 1969.
- Harris R. ACT made simple: an easy-to-read primer on acceptance and commitment therapy: New Harbinger Publications; 2019.
Cited by
Modlin, N. L., Creed, M., Sarang, M., Maggio, C., Rucker, J., & Williamson, V. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s432537 · Cited by 24
“…after PT. Reported changes in self-narratives may be catalysed or accompanied by the previously highlighted mechanisms of change in PT. 56,71,118,119 Further, increases in caring emotional responses towards self, 57 connectedness towards others, 55 experience of positive affect 120 and…”
BackgroundThe Psychedelic Renaissance: A Catholic Perspective
Carroll, T. (2024) · The Linacre Quarterly · doi:10.1177/00243639241274818 · Cited by 5
“A systematic review of the literature around this issue is underway (Johansen et al. 2022), though as of this writing, its results have not yet been reported.”
What are set and setting: Reducing vagueness to improve research and clinical practice
Patch, K., & Smith, W. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251337372 · Cited by 8
“One problem is that PAT research, generally, and set and setting research, in particular, are hindered by inadequate methodological rigor and a lack of clarity on mechanistic hypotheses (Golden et al., 2022; Johansen et al., 2022; Kangaslampi, 2020; Muthukumaraswamy et al., 2021).”
Olson, R. J., Bartlett, L., Sonneborn, A., Milton, R., Bretton-Granatoor, Z., Firdous, A., Harris, A. Z., & Abbas, A. I. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110030 · Cited by 8
Mele, M. L., & Federici, S. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1880744 · Cited by 1
Metadata
- Authors
- Johansen, L., Liknaitzky, P., Nedeljkovic, M., Mastin-Purcell, L., & Murray, G.
- Affiliations
- Swinburne University of Technology (AU)
- Monash University (AU)
- Corresponding author
- Johansen, Lauren
- Venue
- Systematic Reviews
- Published
- 2022-05-05
- Volume
- 11
- Issue
- 1
- Pages
- 85-85
- ISSN
- 2046-4053 (ISSN-L)
- PMC
- PMC9074259
- OpenAlex
- W4229028484
- Cited by
- 11
- References
- 73
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 3 · 2023: 2
- FWCI
- 0.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Systematic Reviews (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Funders
- Australian Government
- Swinburne University of Technology
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- classic psychedelics, psychedelic therapy, depression, psychotherapy, psychedelic-assisted psychotherapy
- MeSH terms
- Systematic Reviews as Topic, Adult, Mental Disorders, Depression, Hallucinogens, Humans, Psychotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol. https://app.cochat.ai/papers/10.1186/s13643-022-01930-7
- The paper
- Johansen, L., Liknaitzky, P., Nedeljkovic, M., Mastin-Purcell, L., & Murray, G. (2022). The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol. Systematic Reviews. https://doi.org/10.1186/s13643-022-01930-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.